Rigel Pharmaceuticals (RIGL) Competitors

Rigel Pharmaceuticals logo
$42.59 -0.33 (-0.77%)
As of 01:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

RIGL vs. XENE, ABCL, PBLS, ACAD, and VKTX

Should you buy Rigel Pharmaceuticals stock or one of its competitors? Rigel Pharmaceuticals's main competitors and comparable companies include Xenon Pharmaceuticals (XENE), AbCellera Biologics (ABCL), Parabilis Medicines (PBLS), ACADIA Pharmaceuticals (ACAD), and Viking Therapeutics (VKTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rigel Pharmaceuticals compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Xenon Pharmaceuticals currently has a consensus target price of $71.15, suggesting a potential upside of 83.48%. Rigel Pharmaceuticals has a consensus target price of $66.75, suggesting a potential upside of 55.52%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Rigel Pharmaceuticals has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xenon Pharmaceuticals$7.50M499.85-$345.91M-$4.70N/A
Rigel Pharmaceuticals$294.28M2.75$367.02M$15.512.77

Xenon Pharmaceuticals has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Rigel Pharmaceuticals has a net margin of 106.59% compared to Xenon Pharmaceuticals' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 14.89% beat Xenon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Xenon PharmaceuticalsN/A -39.81% -37.98%
Rigel Pharmaceuticals 106.59%14.89%11.99%

In the previous week, Xenon Pharmaceuticals had 9 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 13 mentions for Xenon Pharmaceuticals and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.10 beat Xenon Pharmaceuticals' score of -0.28 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xenon Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Rigel Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Rigel Pharmaceuticals beats Xenon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, AbCellera Biologics had 13 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 17 mentions for AbCellera Biologics and 4 mentions for Rigel Pharmaceuticals. AbCellera Biologics' average media sentiment score of 0.64 beat Rigel Pharmaceuticals' score of 0.10 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AbCellera Biologics
3 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rigel Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

AbCellera Biologics presently has a consensus price target of $16.55, indicating a potential upside of 50.00%. Rigel Pharmaceuticals has a consensus price target of $66.75, indicating a potential upside of 55.52%. Given Rigel Pharmaceuticals' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than AbCellera Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AbCellera Biologics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Rigel Pharmaceuticals has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbCellera Biologics$75.13M47.95-$146.41M-$0.48N/A
Rigel Pharmaceuticals$294.28M2.75$367.02M$15.512.77

AbCellera Biologics has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Rigel Pharmaceuticals has a net margin of 106.59% compared to AbCellera Biologics' net margin of -218.54%. Rigel Pharmaceuticals' return on equity of 14.89% beat AbCellera Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
AbCellera Biologics-218.54% -15.35% -10.84%
Rigel Pharmaceuticals 106.59%14.89%11.99%

Summary

Rigel Pharmaceuticals beats AbCellera Biologics on 9 of the 17 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Parabilis Medicines currently has a consensus target price of $40.80, indicating a potential upside of 44.42%. Rigel Pharmaceuticals has a consensus target price of $66.75, indicating a potential upside of 55.52%. Given Rigel Pharmaceuticals' higher possible upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Parabilis Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Parabilis Medicines
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Rigel Pharmaceuticals has higher revenue and earnings than Parabilis Medicines. Parabilis Medicines is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parabilis MedicinesN/AN/A-$145.89M-$2.13N/A
Rigel Pharmaceuticals$294.28M2.75$367.02M$15.512.77

Rigel Pharmaceuticals has a net margin of 106.59% compared to Parabilis Medicines' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 14.89% beat Parabilis Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Parabilis MedicinesN/A -73.69% -25.40%
Rigel Pharmaceuticals 106.59%14.89%11.99%

In the previous week, Parabilis Medicines had 13 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 17 mentions for Parabilis Medicines and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.10 beat Parabilis Medicines' score of 0.05 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Parabilis Medicines
1 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rigel Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Rigel Pharmaceuticals beats Parabilis Medicines on 10 of the 14 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

ACADIA Pharmaceuticals has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$1.07B2.95$391M$2.118.68
Rigel Pharmaceuticals$294.28M2.75$367.02M$15.512.77

Rigel Pharmaceuticals has a net margin of 106.59% compared to ACADIA Pharmaceuticals' net margin of 30.13%. Rigel Pharmaceuticals' return on equity of 14.89% beat ACADIA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals30.13% 8.90% 6.86%
Rigel Pharmaceuticals 106.59%14.89%11.99%

In the previous week, ACADIA Pharmaceuticals had 12 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 16 mentions for ACADIA Pharmaceuticals and 4 mentions for Rigel Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.24 beat Rigel Pharmaceuticals' score of 0.10 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
5 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rigel Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

ACADIA Pharmaceuticals presently has a consensus target price of $31.34, suggesting a potential upside of 71.08%. Rigel Pharmaceuticals has a consensus target price of $66.75, suggesting a potential upside of 55.52%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe ACADIA Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
5 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.72
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

Summary

ACADIA Pharmaceuticals beats Rigel Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Viking Therapeutics?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Rigel Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$294.28M2.75$367.02M$15.512.77
Viking TherapeuticsN/AN/A-$359.64M-$5.40N/A

Rigel Pharmaceuticals presently has a consensus target price of $66.75, suggesting a potential upside of 55.52%. Viking Therapeutics has a consensus target price of $93.36, suggesting a potential upside of 247.33%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Rigel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Viking Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.79

In the previous week, Viking Therapeutics had 13 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 17 mentions for Viking Therapeutics and 4 mentions for Rigel Pharmaceuticals. Viking Therapeutics' average media sentiment score of 0.71 beat Rigel Pharmaceuticals' score of 0.10 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rigel Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Viking Therapeutics
9 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Rigel Pharmaceuticals has a net margin of 106.59% compared to Viking Therapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 14.89% beat Viking Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals106.59% 14.89% 11.99%
Viking Therapeutics N/A -117.35%-88.87%

Rigel Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Summary

Rigel Pharmaceuticals beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RIGL vs. The Competition

MetricRigel PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$805.38M$3.99B$7.64B$11.64B
Dividend YieldN/A3.63%2.47%4.46%
P/E Ratio2.7624.6033.8729.87
Price / Sales2.7315.788.415.67
Price / Cash6.4922.9521.0121.90
Price / Book1.814.174.463.73
Net Income$367.02M-$24.10M$3.51B$394.12M
7 Day Performance-4.12%-7.97%-6.16%-5.97%
1 Month Performance-7.14%-6.07%-4.58%-7.26%
1 Year Performance-7.65%-6.47%-1.48%-7.45%

Rigel Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RIGL
Rigel Pharmaceuticals
4.2106 of 5 stars
$42.48
-1.0%
$66.75
+57.1%
+1.0%$799.73M$294.28M2.74174
XENE
Xenon Pharmaceuticals
2.9841 of 5 stars
$40.45
+3.3%
$71.31
+76.3%
-4.5%$3.79B$7.50MN/A364
ABCL
AbCellera Biologics
4.1909 of 5 stars
$12.50
+5.2%
$15.78
+26.2%
+206.4%$3.77B$75.13MN/A562
PBLS
Parabilis Medicines
2.6846 of 5 stars
$30.37
+6.4%
$40.80
+34.3%
N/A$3.75BN/AN/A145
ACAD
ACADIA Pharmaceuticals
4.7584 of 5 stars
$16.50
-22.3%
$31.55
+91.2%
-23.7%$3.70B$1.07B7.82798

Related Companies and Tools


This page (NASDAQ:RIGL) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners